Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism

Diabetes

Volumn 65, Issue 7, 2016, Pages 2032-2038

  Briand, François ^a   Mayoux, Eric ^b   Brousseau, Emmanuel ^a   Burr, Noémie ^a   Urbain, Isabelle ^a   Costard, Clément ^a   Mark, Michael ^b   Sulpice, Thierry ^a  

^a Physiogenex SAS   (France)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CARBOHYDRATE; CHOLESTEROL; CHOLESTEROL OLEATE; EMPAGLIFLOZIN; FATTY ACID; GLUCOSE; GLYCOGEN; KETONE BODY; LIPID; LIVER PROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLOXAMER; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; COMPARATIVE STUDY; CONFERENCE PAPER; DIET INDUCED DYSLIPIDEMIA; DIET RESTRICTION; DRUG ABSORPTION; DRUG EXCRETION; DYSLIPIDEMIA; ENERGY METABOLISM; ENZYME ACTIVITY; FAST PROTEIN LIQUID CHROMATOGRAPHY; FECES; GLUCOSE BLOOD LEVEL; GLYCOGEN LIVER LEVEL; HAMSTER; IN VIVO STUDY; LIPOLYSIS; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYRIAN HAMSTER; URINARY EXCRETION; ANIMAL; BLOOD; DRUG EFFECTS; DYSLIPIDEMIAS; INTESTINE; LIPID DIET; LIPID METABOLISM; MESOCRICETUS; METABOLISM;

ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CHOLESTEROL, LDL; CRICETINAE; DIET, HIGH-FAT; DYSLIPIDEMIAS; ENERGY METABOLISM; GLUCOSIDES; HYPOGLYCEMIC AGENTS; INTESTINES; LIPID METABOLISM; MALE; MESOCRICETUS;

EID: 84975789692     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0049     Document Type: Conference Paper

References (19)

1. Nauck MA Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 2014;8:1335-1380
2. Vivian EM Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context 2014;3:212264
3. Maliha G, Townsend RR. SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens 2015;9:48-53
4. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015;17:928-935
5. Lund SS, Sattar N, Salsali A, Crowe S, Broedl UC, Ginsberg HN. Potential relevance of changes in haematocrit to changes in lipid parameters with empagliflozin in patients with type 2 diabetes (Abstract). Diabetologia 2015;58(Suppl. 1): S360
6. Briand F, Thieblemont Q, Muzotte E, Sulpice T. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters. Arterioscler Thromb Vasc Biol 2013;33:13-23
7. Briand F, Thiéblemont Q, Muzotte E, Sulpice T. High-fat and fructose intake induces insulin resistance, dyslipidemia, and liver steatosis and alters in vivo macrophage-to-feces reverse cholesterol transport in hamsters. J Nutr 2012; 142:704-709
8. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100:2849-2852
9. Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014;727:66-74
10. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014; 124:499-508
11. Aoki TT Metabolic adaptations to starvation, semistarvation, and carbohydrate restriction. Prog Clin Biol Res 1981;67:161-177
12. Johnston CS, Tjonn SL, Swan PD, White A, Hutchins H, Sears B. Ketogenic low-carbohydrate diets have no metabolic advantage over nonketogenic low-carbohydrate diets. Am J Clin Nutr 2006;83:1055-1061
13. Coffee CJ Branch point in metabolism. In Metabolism. New York, Hayes Barton Press, 2004, p. 163
14. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A 1999;96: 11041-11048
15. Singh AB, Kan CF, Shende V, Dong B, Liu J. A novel posttranscriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression. J Lipid Res 2014;55:1397-1407
16. Ferrières J. Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins. Am J Cardiovasc Drugs 2009;9: 109-115
17. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
18. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009;50(Suppl.):S189-S194
19. Miettinen TA, Gylling H, Viikari J, Lehtimäki T, Raitakari OT. Synthesis and absorption of cholesterol in Finnish boys by serum non-cholesterol sterols: the cardiovascular risk in Young Finns Study. Atherosclerosis 2008;200:177-183